spacer
home > > summer 2009 > feasibility studies: the road to success
PUBLICATIONS


Feasibility Studies: The Road to Success

In the extremely competitive world of the pharmaceutical industry, success often means being the first. And being the first means launching your new product on the market while leaving your competitors behind. In clinical research, the recruitment of the right patient population within the planned timelines is the most important factor in ensuring success. And because ‘time is money’, respecting timelines also means remaining within the available budget allocated for a clinical research project: this is what a sponsor expects from a CRO and this is what a CRO should be ready to offer to the pharmaceutical industry.

The selection of the right countries and investigational sites is the leading factor for a successful trial. Even when the regulatory process takes longer than expected, these appropriately chosen sites will help you in recovering this extra time by reducing the recruitment period and ensuring 100 per cent of patients are enrolled within timelines.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Margherita Mosconi is the Client Project Operations Director of CROM srl. After her PhD in Biological Science, she joined a major global pharmaceutical company and, over the subsequent 11 years, progressed through roles in national and international project management in a variety of therapeutic areas. She then joined CROM in January 2005 and has since overseen the operational delivery of hundreds of trials at all phases of development. Margherita is now responsible for new business opportunities and oversees the contracts, bids and proposals. She also liaises and works closely with CROM clients to optimise ongoing operational processes.

Davide Garrisi is Clinical Research Leader of the International Trials Department of CROM srl. Before joining CROM in 2005, he spent two years in quality assurance and regulatory affairs in the bulk pharmaceutical industry, where he was responsible for validation activities, quality system management (ISO, GMP), regulatory applications of drug master files, and having contact with regulatory authorities. He was also member of the internal Quality System Inspectors Team. Davide is now responsible for the supervision and management of several clinical trials in a variety of therapeutic fields.

spacer
Margherita Mosconi
spacer
spacer
spacer
Davide Garrisi
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IONTAS announces a new collaboration to identify novel immunotherapy targets

Cambridge, UK, 07 May 2020: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement